PAVEL, M.E., S. SINGH, J.R. STROSBERG, L. BUBUTEISHVILI-PACAUD, E. DEGTYAREV, M.P. NEARY, C. CARNAGHI,
Jiří TOMÁŠEK, E. WOLIN, M. RADERER, H. LAHNER, J.W. VALLE, R. POMMIER, E. VAN CUTSEM, M.E.T. TESSELAAR, G. DELLE FAVE, R. BUZZONI, M. HUNGER, J. ERIKSSON, D. CELLA, J.F. RICCI, N. FAZIO, M.H. KULKE a J.C. YAO. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncology. New York: Elsevier Science INC, 2017, roč. 18, č. 10, s. 1411-1422. ISSN 1470-2045. Dostupné z: https://dx.doi.org/10.1016/S1470-2045(17)30471-0.